Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Cabaletta Bio (CABA) Slides -38% in 30 Days as Shares Fall Below $1

Cabaletta Bio (CABA) Slides -38% in 30 Days as Shares Fall Below $1

Key Takeaways

  • Cabaletta Bio (CABA) fell roughly 38% over the trailing 30 days, sliding from about $1.54 to approximately $0.95.
  • The move extends a broader decline that has taken the stock below the $1 level, a threshold closely watched for potential exchange-listing considerations.
  • Third-quarter 2026 results showed a widening net loss of $53.1 million as research and development spending rose, even though EPS of -$0.28 beat consensus estimates.
  • Positive rese-cel clinical data presented at ACR Convergence 2026 did not halt the selloff, signaling that financing and dilution concerns outweighed near-term clinical news.
  • The company's $299.4 million cash position is expected to fund operations into Q1 2028, but management has indicated additional financing will be required.
  • Over the past quarter, the stock has declined roughly 70% from around $3.19, reflecting sustained selling pressure across the second half of the year.
  • For additional detail on valuation and estimates, explore Cabaletta Bio's Price Targets, Earnings, and Forecast pages.
  • For automated trading signals and ideas, explore Trending AI Robots.

Cabaletta Bio (CABA) Company Overview and Market Position

Cabaletta Bio, Inc. is a late-stage clinical biotechnology company based in Philadelphia that is developing targeted cell therapies designed specifically for patients with autoimmune diseases. Its lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-directed CAR T-cell therapy being evaluated across a broad RESET clinical program spanning rheumatology, neurology, and dermatology, including myositis, systemic lupus erythematosus and lupus nephritis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

The company's strategic focus is on delivering potentially curative, deep, and durable responses while simplifying the treatment experience through weight-based dosing, a no-preconditioning approach in select indications, and automated manufacturing through its partnership with Cellares. I follow CABA closely because it represents a differentiated play on the emerging cell-therapy-for-autoimmune-disease opportunity, with a registrational myositis study underway and a planned BLA submission for rese-cel. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Cabaletta Bio (CABA) Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, CABA shares have fallen approximately 38%, declining from a closing level of about $1.54 to roughly $0.95. The move was broadly one-directional, with only brief and short-lived rebounds, including a temporary bounce in early November that quickly faded as the stock resumed its downtrend.

The quarterly picture is even more pronounced. Roughly three months ago, the stock traded near $3.19, meaning it has declined approximately 70% over the trailing quarter. After peaking near $3.57 in early September, the shares have printed a persistent series of lower highs and lower lows, with the downtrend accelerating through October and into November as the stock crossed below the $1 mark.

What Drove CABA Stock Price in the Last 30 Days

The most significant development in the period was the company's third-quarter 2026 financial report, which showed a net loss of $53.1 million, up from $44.9 million a year earlier, driven by higher research and development spending tied to advancing rese-cel trials and manufacturing readiness. Although the reported EPS of -$0.28 modestly beat consensus expectations, the market appeared to focus on rising cash burn and the company's statement that additional financing will be needed to complete clinical development.

Positive clinical data released at ACR Convergence 2026 did not reverse the slide. The presentation showed that all six dermatomyositis patients maintained immunomodulator-free responses through one year and that all five lupus nephritis patients with follow-up achieved a DORIS response. Despite this, the stock continued to fall, suggesting that dilution risk, funding concerns, and broader risk-off sentiment in small-cap biotech outweighed the favorable data. The breach below $1 added further technical and psychological pressure on the shares. From what I see, this reaction highlights how financing worries can dominate even solid clinical updates in this sector.

What Drove CABA Stock Performance Over the Last Quarter

The quarterly decline reflects a shift from optimism earlier in the year to sustained selling pressure in the second half. The stock had previously rallied on encouraging EULAR 2026 data and a $150 million financing that included participation from Eli Lilly, which strengthened the balance sheet and supported a 2H27 BLA timeline for rese-cel in myositis.

However, as the year progressed, rising operating expenses, widening losses, and the prospect of additional equity financing created an overhang on the shares. A succession of positive data readouts failed to generate durable buying, and the stock steadily gave back its earlier gains as investors re-rated the risk-reward in light of the company's cash needs and the extended timeline to a potential BLA submission in Q1 2028. This is important because it shows how quickly sentiment can shift when capital requirements come into focus.

CABA Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the primary catalyst for Cabaletta Bio is the RESET-Myositis registrational trial, with topline results anticipated in the second half of 2027 and a planned BLA submission in Q1 2028. The company has also indicated that go-forward development plans for preconditioning-free dosing in lupus and generalized myasthenia gravis are expected in the first half of 2027.

Investors will likely monitor the company's cash position and any additional financing activity, given management's guidance that further capital will be required. Broader factors, including the interest-rate environment, biotech risk appetite, regulatory interactions with the FDA, and manufacturing-readiness milestones with Cellares, may also influence sentiment. As with any clinical-stage biotechnology company, trial outcomes, safety data, and timing shifts remain key risks that could materially affect the stock. I’m watching this closely as the timeline to potential approval stretches out.

Using Tickeron’s AI Tools for Deeper Analysis

In my own research process, I frequently rely on Tickeron’s AI Trend Prediction Engine to cross-reference potential price movements and compare them against my fundamental views on names like CABA. This platform offers a systematic way to scan for patterns and signals across thousands of tickers, helping me stay objective when clinical-stage biotech names face volatility. It serves as a useful complement to traditional analysis without replacing personal judgment on factors like cash runway or trial timelines.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CABA

Contributor

Dem Sem's AvatarDem Sem|Expert

CABA's RSI Oscillator is sitting in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 80 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for CABA turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CABA entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.596). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases

Industry Biotechnology

Industry
N/A
Address
2929 Arch Street
Phone
+1 267 759-3100
Employees
156
Web
https://www.cabalettabio.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Cabaletta Bio (CABA) Slides -38% in 30 Days as Shares Fall Below $1